top of page

From Seoul: AimedBio is leveraging patient data and its expertise in antibody discovery and design to develop first-in-class antibody-drug conjugates with unique targets - the first program is FGFR3

Nov 20, 2024
1 min read

CEO Nam-Gu Her describes the factors that make AimedBio unique in how it designs ADCs, and discusses how it landed on FGFR3 as its first target. While the company has at first focused on the antibody side, it is now also developing its own proprietary linker-payload combinations.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page